Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double-blind, placebo-controlled, parallel group multicenter study to assess the safety, tolerance and efficacy of a single subcutaneous dose of tezampanel in patients with acute migraine.

X
Trial Profile

A double-blind, placebo-controlled, parallel group multicenter study to assess the safety, tolerance and efficacy of a single subcutaneous dose of tezampanel in patients with acute migraine.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2009

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tezampanel (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Sponsors Raptor Pharmaceutical Corp
  • Most Recent Events

    • 30 Jun 2008 Primary endpoint met, according to interim results presented at the 50th Annual Scientific Meeting of the American Headache Society, as reported in a TorreyPines media release (9090616).
    • 13 May 2008 Results will be presented at the 2008 AHS Scientific Meeting, according to a TorreyPines media release.
    • 22 Oct 2007 Status changed from in progress to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top